Your browser doesn't support javascript.
loading
Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection.
Du, Yi-Qi; Su, Tun; Fan, Jian-Gao; Lu, Yu-Xia; Zheng, Ping; Li, Xing-Hua; Guo, Chuan-Yong; Xu, Ping; Gong, Yan-Fang; Li, Zhao-Shen.
Afiliación
  • Du YQ; Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
World J Gastroenterol ; 18(43): 6302-7, 2012 Nov 21.
Article en En | MEDLINE | ID: mdl-23180952
ABSTRACT

AIM:

To investigate whether the addition of probiotics can improve the eradication effect of triple therapy for Helicobacter pylori (H. pylori) infection.

METHODS:

This open randomized trial recruited 234 H. pylori positive gastritis patients from seven local centers. The patients were randomized to one-week standard triple therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid; OCA group, n = 79); two weeks of pre-treatment with probiotics, containing 3 × 10(7)Lactobacillus acidophilus per day, prior to one week of triple therapy (POCA group, n = 78); or one week of triple therapy followed by two weeks of the same probiotics (OCAP group, n = 77). Successful eradication was defined as a negative C13 or C14 urease breath test four weeks after triple therapy. Patients were asked to report associated symptoms at baseline and during follow-up, and side effects related to therapy were recorded. Data were analyzed by both intention-to-treat (ITT) and per-protocol (PP) methods.

RESULTS:

PP analysis involved 228 patients, 78 in the OCA, 76 in the POCA and 74 in the OCAP group. Successful eradication was observed in 171 patients; by PP analysis, the eradication rates were significantly higher (P = 0.007 each) in the POCA (62/76; 81.6%, 95% CI 72.8%-90.4%) and OCAP (61/74; 82.4%, 95% CI 73.6%-91.2%) groups than in the OCA group (48/78; 61.5%, 95% CI 50.6%-72.4%). ITT analysis also showed that eradication rates were significantly higher in the POCA (62/78; 79.5%, 95% CI 70.4%-88.6%) and OCAP (61/77; 79.2%, 95% CI 70%-88.4%) groups than in the OCA group (48/79; 60.8%, 95% CI 49.9%-71.7%), (P = 0.014 and P = 0.015). The symptom relieving rates in the POCA, OCAP and OCA groups were 85.5%, 89.2% and 87.2%, respectively. Only one of the 228 patients experienced an adverse reaction.

CONCLUSION:

Administration of probiotics before or after standard triple therapy may improve H. pylori eradication rates.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter / Probióticos / Inhibidores de la Bomba de Protones / Lactobacillus acidophilus / Antibacterianos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline País/Región como asunto: Asia Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2012 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter / Probióticos / Inhibidores de la Bomba de Protones / Lactobacillus acidophilus / Antibacterianos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline País/Región como asunto: Asia Idioma: En Revista: World J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2012 Tipo del documento: Article